Description
The global antiparasitic drugs market was valued at USD 20.3 billion in 2025 and is projected to reach USD 30.1 billion by 2032, growing at a CAGR of 5.8% during the forecast period. Antiparasitic drugs are medications used to prevent, manage, and treat infections caused by parasitic organisms, including protozoa, helminths, and ectoparasites. These organisms can affect the gastrointestinal tract, bloodstream, skin, liver, lungs, central nervous system, and other organ systems, creating a broad clinical need for targeted therapeutic intervention. The market includes anthelmintics, antiprotozoal drugs, ectoparasiticides, and other drug classes administered through oral, injectable, and topical routes. These therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used across endemic regions, travel medicine, public health programs, hospital care, and community-based treatment settings.
The market plays a critical role in global infectious disease control because parasitic infections remain a major public health burden across both endemic and non-endemic regions. In low- and middle-income countries, the demand is closely linked to soil-transmitted helminth infections, malaria, leishmaniasis, schistosomiasis, giardiasis, toxoplasmosis, and other parasitic diseases. In developed markets, demand is supported by imported infections, foodborne parasitic diseases, zoonotic transmission, immunocompromised patient care, and travel-related diagnosis. The market is also supported by large-scale deworming programs, malaria elimination strategies, neglected tropical disease initiatives, public awareness campaigns, and improved diagnostic access. As global travel, migration, climate variability, and cross-border disease transmission reshape infection patterns, antiparasitic drugs are expected to remain essential to both routine clinical care and population-level disease prevention.
Growth is being driven by the rising prevalence of parasitic infections, increasing government initiatives and funding, expanding public health programs, and growing awareness of early diagnosis and treatment. Innovation is gradually shifting the market toward next-generation antiparasitic drugs, combination therapies, improved formulations, resistance-management strategies, and broader access models in high-burden regions. At the same time, drug resistance and limited novel drug pipelines remain important constraints, particularly where long-standing therapies are used repeatedly across mass drug administration programs. Over the forecast period, the market is expected to evolve from a largely established-drug and program-led category into a more innovation-driven therapeutic area, shaped by affordable generics, public-private partnerships, clinical trial activity, digital pharmacy access, and targeted treatment strategies for both endemic and emerging parasitic disease settings.
Key Highlights of the Report
• The global antiparasitic drugs market is expected to expand steadily through the forecast period, supported by the persistent burden of parasitic infections across endemic and non-endemic regions. Growing public health awareness, improved diagnostic access, government-led disease control initiatives, and wider availability of essential medicines are strengthening treatment uptake across hospitals, retail pharmacies, and digital pharmacy channels.
• In terms of drug type, anthelmintics dominate the global antiparasitic drugs market, driven by the high prevalence of helminthic infections and their continued use in deworming programs. These drugs remain critical in treating intestinal worms, roundworms, tapeworms, and flukes, particularly in regions where sanitation gaps, tropical climates, and mass treatment campaigns continue to influence demand.
• Antiprotozoal drugs are projected to record the fastest growth, supported by the rising burden of protozoal infections such as malaria, giardiasis, leishmaniasis, and other parasite-related diseases. The segment is also gaining momentum due to the development of combination therapies, stronger malaria-control programs, and increasing focus on resistance-management strategies.
• Ectoparasiticides remain an important treatment category, supported by ongoing demand for therapies targeting parasites that affect the skin, hair, and external body surfaces. These products are particularly relevant in the management of lice, mites, scabies, and other external parasitic infestations, where localized treatment and convenient application formats are preferred.
• Other antiparasitic drug types continue to support the market where specialized parasitic infections require targeted, disease-specific treatment protocols. This category remains relevant for less common or complex infections that may not be addressed by broad-spectrum therapies and often require physician-supervised selection based on diagnosis, severity, and parasite type.
• Based on route of administration, oral formulations dominate the market, driven by ease of administration, strong patient compliance, broad availability, and suitability for both individual treatment and mass drug administration programs. Oral antiparasitic drugs are particularly important in public health campaigns because they are easier to distribute, store, and administer across large patient populations.
• Topical formulations are emerging as a fast-growing route of administration, supported by demand for targeted treatment, localized drug delivery, and reduced systemic exposure. These formulations are especially useful for ectoparasitic infections, where direct application to the affected area can improve convenience, support faster symptom relief, and enhance patient adherence.
• Injectable therapies remain clinically important for severe, complicated, or hospital-managed parasitic infections where close monitoring and controlled administration are required. These treatments are often used when oral therapy is not suitable, when rapid drug action is needed, or when patients require specialist care due to disease severity or systemic involvement.
• Based on distribution channel, hospital pharmacies dominate the market, driven by their role in managing severe infections, supporting physician-supervised therapy, and ensuring appropriate drug selection and dosing. Hospital pharmacies are especially important for complicated cases, inpatient treatment, injectable therapy, and infections requiring diagnostic confirmation and clinical monitoring.
• Retail pharmacies continue to remain relevant for community-level access, outpatient treatment, repeat prescriptions, and preventive therapy. They play a key role in improving treatment availability for common parasitic infections, particularly where patients require convenient access to physician-prescribed or pharmacist-supported antiparasitic medicines.
• Online pharmacies are projected to record the fastest growth, supported by increasing digital health adoption, e-prescriptions, teleconsultations, and consumer preference for convenient medicine access. This channel is becoming particularly important for patients seeking faster procurement, discreet treatment options, and improved access in areas where physical pharmacy reach may be limited.
• By region, North America dominates the global antiparasitic drugs market, primarily driven by advanced healthcare infrastructure, strong diagnostic capabilities, high treatment accessibility, and well-established disease surveillance systems. Demand in the region is shaped by imported infections, zoonotic transmission, foodborne parasitic diseases, travel-related cases, and treatment needs among immunocompromised patients.
• Asia Pacific is projected to be the fastest-growing regional market, supported by tropical disease prevalence, large population base, expanding healthcare access, and government-led initiatives targeting deworming, malaria control, and neglected tropical diseases. The region’s growth is further strengthened by increasing awareness, improving diagnostic infrastructure, and rising investment in public health programs.
• Europe remains a significant market, supported by strict hygiene standards, coordinated parasite monitoring, cross-border disease surveillance, and strong food safety systems. The region’s demand is influenced by travel-related parasitic infections, zoonotic disease monitoring, imported cases, and advanced laboratory capabilities that support early diagnosis and appropriate treatment.
• Latin America represents an important growth region, supported by the continued burden of tropical and parasitic diseases, public healthcare programs, and government-led awareness campaigns. Improved access to essential medicines, partnerships with global pharmaceutical companies, and strengthening of local manufacturing capabilities are expected to support wider treatment availability.
• The Middle East and Africa market is gaining relevance as healthcare investments, national disease-control programs, and improved infectious disease screening infrastructure strengthen diagnosis and treatment access. Growth in the region is also supported by public health modernization, rising focus on parasitic disease management, and expanding access to hospital and community-based treatment channels.
• The competitive landscape is moderately consolidated, with GlaxoSmithKline leading the market through its established antiparasitic portfolio and strong participation in global deworming and neglected tropical disease initiatives. Leading companies are maintaining competitiveness through broad therapeutic coverage, global manufacturing capacity, strong distribution networks, public health partnerships, and affordable treatment access.
• Leading companies are competing through product portfolio expansion, generic drug availability, improved formulations, combination therapies, global supply partnerships, and resistance-focused clinical development. As drug resistance becomes a growing concern, long-term differentiation will increasingly depend on innovation, affordability, regulatory approvals, and the ability to support large-scale disease-control programs across high-burden markets.
Key Company Profiles
• AdvaCare Pharma
• Ajanta Pharma
• Alkem Laboratories
• Cadila Pharmaceuticals
• Cipla
• Dr. Reddy’s Laboratories
• GlaxoSmithKline
• Intas Pharmaceuticals
• Ipca Laboratories
• Mankind Pharma
• Novartis
• Sanofi
• Teva Pharmaceuticals
• Weefsel Pharma
• Zydus Lifesciences
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
